Northwest Biotherapeutics, Inc.
NWBO
$0.17
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 63.36% | -26.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 63.36% | -26.49% | |||
| Cost of Revenue | 17.44% | -12.53% | |||
| Gross Profit | -12.24% | 10.61% | |||
| SG&A Expenses | 2.62% | -24.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.93% | -19.62% | |||
| Operating Income | -6.47% | 19.28% | |||
| Income Before Tax | -200.46% | -460.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -200.46% | -321.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -200.46% | -321.11% | |||
| EBIT | -6.47% | 19.28% | |||
| EBITDA | -6.93% | 20.72% | |||
| EPS Basic | -176.19% | -362.50% | |||
| Normalized Basic EPS | -155.00% | 66.67% | |||
| EPS Diluted | -176.19% | -200.00% | |||
| Normalized Diluted EPS | -155.00% | 66.67% | |||
| Average Basic Shares Outstanding | 3.63% | 3.22% | |||
| Average Diluted Shares Outstanding | 3.63% | 3.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||